medRxiv : the preprint server for health sciences · 2025
Pittsburgh plasma p-tau217: classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community.
СтатьяПрепринтНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sehrawat Anuradha, Zeng Xuemei, Abrahamson Eric E, Deek Rebecca A, Gogola Alexandra, Kamboh M Ilyas, Pascoal Tharick A, Villemagne Victor L, Lopez Oscar L, Ikonomovic Milos D, Snitz Beth E, Cohen Ann D, Karikari Thomas K
Аннотация
INTRODUCTION: Most available p-tau217 immunoassays have similar performances. It is unclear if this is due to the use of the same antibody (the "ALZpath antibody"). We established and evaluated a novel p-tau217 assay that employs an alternative antibody, and benchmarked the results against ALZpath-p-tau217.
METHODS: Following development and analytical validation of the University of Pittsburgh ("Pitt-p-tau217") method, clinical verification was performed in three independent cohorts (n=363).
RESULTS: Pitt-p-tau217 demonstrated high between-run stability, linearity, and specificity. Clinically, Pitt-p-tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with AUC=0.94, and Aβ-PET-positive from Aβ-PET-negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath-p-tau217 results. Both Pitt-p-tau217 and ALZpath-p-tau217 were elevated in tau-PET-positive versus tau-PET-negative participants (P=0.06; AUC=0.71 for both). Between-assay correlations were up to 0.93.
DISCUSSION: The new Pitt-p-tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of AD, equivalent to the widely used ALZpath-p-tau217.
METHODS: Following development and analytical validation of the University of Pittsburgh ("Pitt-p-tau217") method, clinical verification was performed in three independent cohorts (n=363).
RESULTS: Pitt-p-tau217 demonstrated high between-run stability, linearity, and specificity. Clinically, Pitt-p-tau217 differentiated neuropathologically confirmed PSEN1 mutation carriers from controls with AUC=0.94, and Aβ-PET-positive from Aβ-PET-negative cognitively normal older adults with AUC up to 0.84, equivalent to ALZpath-p-tau217 results. Both Pitt-p-tau217 and ALZpath-p-tau217 were elevated in tau-PET-positive versus tau-PET-negative participants (P=0.06; AUC=0.71 for both). Between-assay correlations were up to 0.93.
DISCUSSION: The new Pitt-p-tau217 assay exhibits high and reproducible classification accuracies for identifying individuals with biological evidence of AD, equivalent to the widely used ALZpath-p-tau217.